The company posted a net profit of ₹9.7 crore for Q4FY26, compared with a loss of ₹4.8 crore in the corresponding quarter last year. Revenue rose 42% year-on-year to ₹387.3 crore from ₹273 crore, while EBITDA increased 35.3% to ₹58 crore from ₹43 crore a year earlier.
EBITDA margin, however, narrowed slightly to 14.9% from 15.6% in the year-ago quarter.
Following the earnings announcement, shares of Solara Active Pharma Sciences surged nearly 15% to ₹583 on the NSE during afternoon trade.
The company said overall performance in Q4 reflected sequential growth of 12% and year-on-year growth of 40%, adding that it recorded its highest revenue, gross margin and EBITDA in the last eight quarters.
Managing Director and CEO Sandeep Rao said the company’s “base business” continued to demonstrate stronger profitability, operating at around 26% EBITDA margin with gross margins of nearly 54%. He added that the company’s strategy to shift away from a reset phase towards sustainable and profitable growth was beginning to deliver results.
However, Solara flagged continued challenges in the commodity Ibuprofen segment, which reported negative EBITDA margins of 21% amid weak pricing and global oversupply pressures. The company said it has appointed bankers to evaluate strategic options for the business to ensure long-term value creation.
Solara added that regulated markets continued to contribute nearly 75% of total revenue, supported by a healthy product mix and resilient demand across key geographies. The company also said its focus on expanding the base business was helping reduce exposure to commodity pricing volatility in the global Ibuprofen market.
